ClinicalTrials.gg
CompletedNCT02214147Updated Nov 15, 2018Results posted

Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function

A Phase 1 interventional study of Alisertib in Advanced Solid Tumors and Relapsed/Refractory Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-15.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Lymphoma by Takeda — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Takeda.

Enrollment
12th of 23
36 · median 36
Started
2014
with 4 others
Phase 1
12 of 26
none open now
Registered
18th of 26
by date

Among the 26 studies in Lymphoma by Takeda, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2014, is one of 12 in phase 1, and was the 18th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

1 of the 26 studies in Lymphoma by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Lymphoma by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of moderate or severe hepatic impairment on the single-dose pharmacokinetics of alisertib in adult participants with cancer.

Read the detailed description

The drug being tested in this study is called alisertib. Alisertib was tested to assess how it was processed by the body in participants with advanced solid tumors or relapsed/refractory lymphoma with varying degrees of liver function. This study also assessed laboratory results and safety.

The study enrolled 36 participants. Participants were assigned to 1 of the 3 treatment groups based on the status of their liver function: Normal hepatic function (Total bilirubin ≤ upper limit of the normal range [ULN] and alanine aminotransferase [ALT] level ≤ ULN), moderate hepatic impairment (Total bilirubin > 1.5-3 x ULN and ALT level = Any), or severe hepatic impairment (Total bilirubin > 3 x ULN and ALT level = Any). All participants were administered one 50 mg dose of alisertib on Day 1, Cycle 1. Alisertib was administered again on Days 8 through 14 of Cycle 1, followed by a 14-day rest period. Doses administered on Days 8-14 were 50, 30, or 20 mg of alisertib, depending on hepatic function. Alisertib was then continued at the same dose as in Cycle 1, Days 8-14 in 21-day cycles (7 days of alisertib followed by a 14-day rest period) for up to 1 year (approximately 16 cycles).

This multicenter trial was conducted in USA only. The overall time to participate in this study was up to 312 Days. Participants made multiple visits to the clinic including an end-of-study visit 30 days after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Advanced Solid Tumors
  • Relapsed/Refractory Lymphoma

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants 18 years of age or older.
  2. or cytologically confirmed and/or advanced solid tumors or lymphomas for which standard curative or life-prolonging treatment does not exist or is no longer effective or tolerable.
  3. (ECOG) performance status of 0 to 2.
  4. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 2 effective methods of , at the same time, from the time of signing the through 30 days after the last dose of study drug, or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception).
  5. Male participants, even if surgically sterilized (ie, status postvasectomy), who:

    • Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug, or
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant (periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] and withdrawal are not acceptable methods of contraception).
  6. Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.
  7. Suitable venous access for the study-required blood sampling, including pharmacokinetics.
  8. Ability to swallow tablets.
  9. Participants with biliary obstruction for which a stent had been placed are eligible provided that the stent has been in place for more than 14 days before the first dose of alisertib and liver function has stabilized.
  10. Recovered from the reversible effects of prior antineoplastic therapy (ie, ≤ Grade 1 toxicity or baseline).
  11. Clinical laboratory values as specified below:

    • (ANC) ≥ 1500/μL and count ≥ 75,000/μL.

      • Participants with normal hepatic function: Total and (ALT) must be ≤ (ULN).
      • Participants with moderate hepatic impairment: total bilirubin must be > 1.5 to 3 x ULN with any ALT level.
      • Participants with severe hepatic impairment: total bilirubin must be > 3 x ULN with any ALT level.
      • Measured or calculated creatinine clearance > 30 mL/minute. Note: If a calculated creatinine clearance is used, it should be calculated according to the Cockcroft-Gault formula.
      • must be ≥ 8 g/dL.

Exclusion criteria

Exclusion Criteria:

  1. Participants of North/East Asian ethnicity (ie, Japanese, Chinese, Korean) will be excluded.
  2. Recurrent nausea and/or vomiting within 14 days before the first dose of alisertib or known gastrointestinal (GI) abnormality or GI procedure that could interfere with or modify the oral absorption or tolerance of alisertib. Examples include, but are not limited to, disease-related bowel obstruction, pancreatic insufficiency, use of pancreatic enzymes, a gastric condition (such as severe reflux or active peptic ulcer disease) that requires chronic and uninterrupted use of proton pump inhibitors, partial gastrectomy, history of small intestine surgery, and celiac disease.
  3. Participants requiring treatment with enzyme inducers, such as the enzyme-inducing anti-epileptic drugs phenytoin, carbamazepine, phenobarbital, oxcarbazepine, primidone, rifampin, rifabutin, rifapentine, or St. John's wort within 14 days before the first dose of alisertib or requiring the use of these medications during the study.
  4. A medical condition requiring use of pancreatic enzymes; daily, chronic, or regular use of proton pump inhibitors (PPIs); or histamine 2 (H2) receptor antagonists. Participants who intermittently use these medications, must meet the following criteria:

    • No use of PPIs within 5 days before the first dose of alisertib.
    • No use of H2 antagonist or pancreatic enzymes within 24 hours before the first dose of alisertib.
  5. Inadequate bone marrow or other organ function (excluding hepatic impairment per eligibility criteria).
  6. Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of alisertib.
  7. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  8. Treatment with any anticancer therapy or any products within 3 weeks before the first dose of study drug.
  9. Exposure to nitrosoureas or mitomycin C within 42 days before the first dose of study drug.
  10. Radiotherapy within 14 days before the first dose of study drug.
  11. Prior treatment with radiation therapy involving ≥ 25% of the hematopoietically active bone marrow within 42 days before the first dose of study drug.
  12. Major surgery within 14 days before the first dose of study drug.
  13. Serious infection within 14 days before the first dose of study drug. Participant must have recovered from infection before first dose.
  14. Life-threatening illness unrelated to cancer.
  15. Symptomatic . Participants with brain metastases:

    • Must have stable neurologic status following local therapy (surgery or radiation) for at least 2 weeks after completion of the definitive therapy AND
    • Must be without neurologic dysfunction that would confound the evaluation of neurologic or other adverse events (AEs).
  16. Clinically significant coagulopathy or bleeding disorder.
  17. Severe central nervous system, pulmonary, or renal disease not related to the participant's cancer.
  18. Known (HIV) positive.
  19. Known history of infection or suspected currently active hepatitis C infection, or known or suspected history of infection. Participants with known or suspected history of hepatitis B infection were to be screened and excluded when any of the following conditions were met:

    • Received hematopoietic stem cell transplantation (either allogeneic or autologous), or
    • Received any rituximab-containing treatment regimen in the last 12 months before entering the study, or
    • Tested positive for the presence of at least 1 of the following 3 markers in blood (evaluated at Screening): hepatitis B surface antigen (HBsAg), antibodies against hepatitis B core antigen (anti-HBc), or hepatitis B virus deoxyribonucleic acid (HBV DNA).
  20. Any of the following cardiovascular conditions:

    • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
    • interval (QTc) > 500 milliseconds in a 12-lead (ECG) during screening.
  21. History of uncontrolled sleep apnea syndrome or other condition that could result in excessive daytime sleepiness, such as severe .
  22. Use of moderate or strong cytochrome P450 (CYP) 3A inhibitors or inducers within 2 weeks before the first dose of study drug.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Alisertib: Normal Hepatic Function

    Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 50 mg, orally, twice daily (BID) for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 50 mg, BID for 7 days, followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Normal hepatic function includes participants with total bilirubin ≤ upper limit of the normal range \[ULN\] and alanine aminotransferase \[ALT\] level ≤ ULN.

    Drug: Alisertib

  • Experimental
    Alisertib: Moderate Hepatic Impairment

    Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by alisertib 30 mg, BID for 7 days (Cycle 1 Day 8 to 14), followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 30 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Moderate hepatic impairment includes participants with total bilirubin \> 1.5-3 x ULN and any ALT level.

    Drug: Alisertib

  • Experimental
    Alisertib: Severe Hepatic Impairment

    Alisertib 50 mg, orally, once, on Cycle 1 Day 1, followed by, alisertib 20 mg, BID for 7 days (Cycle 1 Day 8 to 14) followed by a 14-day rest period. Starting at Cycle 2 Day 1, alisertib 20 mg, BID for 7 days followed by a 14-day rest period unless a dose reduction is indicated. Participants may continue to receive alisertib until they experience progressive disease or unacceptable alisertib-related toxicities for up to 12 months (approximately 16 cycles), unless it is determined by the investigator, with agreement by the sponsor, that a participant would derive clinical benefit from continued treatment beyond 12 months. Severe hepatic impairment includes participants with total bilirubin \> 3 x ULN and any ALT level.

    Drug: Alisertib

Interventions

  • Alisertib will be supplied as enteric coated tablets.

    Also known as: MLN8237

06

What researchers measure

Primary outcomes

  1. Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib

    Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose

  2. Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib

    Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose

  3. Unbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib

    Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose

Secondary outcomes

  1. Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event

    An adverse event is any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Baseline to 30 days after last dose (Up to 312 Days)

  2. Percentage of Participants Who Experienced at Least 1 Serious Adverse Event

    A serious adverse event is any untoward medical occurrence or effect that at any dose of a drug results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important due to other reasons than the above mentioned criteria.

    Time frame: Baseline to 30 days after last dose (Up to 312 Days)

  3. Percentage of Participants With Clinically Significant Laboratory Values

    Laboratory assessments include serum chemistry and hematology. An abnormal laboratory value was assessed as an AE if that value led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline.

    Time frame: Baseline to the end of the study (Up to 312 Days)

  4. Percentage of Participants With Clinically Significant Vital Signs

    Vital signs include measurements of sitting diastolic and systolic blood pressure, heart rate, and temperature. Any vital signs determined by the investigator to be clinically significant were recorded as AEs.

    Time frame: Baseline to the end of the study (Up to 312 days)

  5. Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2

    Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose

  6. Tmax: Time of First Occurrence of Cmax for Alisertib Metabolites M1 and M2

    Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose

  7. AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2

    The area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-last) of the alisertib metabolites M1 and M2 was determined from the concentration-time curve of each participant using non-compartmental methods.

    Time frame: Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose

  8. Dose-normalized Trough Concentration of Alisertib on Cycle 1 Day 14

    A single blood sample will be collected pre-dose on Cycle 1 Day 14. The concentration of alisertib was determined in the plasma sample and dose-normalized.

    Time frame: Pre-dose on Day 14 of Cycle 1

07

Results

Posted Nov 15, 2018

Participant flow

Participants took part in the study at 6 investigative sites in the United States from 21 August 2014 to 18 July 2016.

Participant flow — Overall Study
MilestoneAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Started16128
Completed16128
Not completed000

Outcome measures

PrimaryUnbound Cmax: Maximum Observed Plasma Concentration for Alisertib
Time frame:
Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Reported as:
Mean · nmol/L
Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib
nmol/LAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Unbound Cmax: Maximum Observed Plasma Concentration for Alisertib17.3 ± 9.0928.1 ± 7.8218.5 ± 5.80
Statistical analysis
  • Alisertib: Normal Hepatic Function vs Alisertib: Moderate Hepatic Impairment vs Alisertib: Severe Hepatic Impairment · Least squares geometric mean ratio: 1.42 · 90% CI 1.12 to 1.80Least Squares Geometric Means Ratio= Moderate + Severe Hepatic Impairment/Normal Hepatic Function
PrimaryUnbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib
Time frame:
Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Reported as:
Mean · h*nmol/L
Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib
h*nmol/LAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Unbound AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib248.5 ± 131.41859.1 ± 387.85735.4 ± 444.61
Statistical analysis
  • Alisertib: Normal Hepatic Function vs Alisertib: Moderate Hepatic Impairment vs Alisertib: Severe Hepatic Impairment · Least squares geometric mean ratio: 3.21 · 90% CI 2.33 to 4.43Least Squares Geometric Mean Ratio=Moderate + Severe Hepatic Impairment/Normal Hepatic Function
PrimaryUnbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib
Time frame:
Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Reported as:
Mean · h*nmol/L
Unbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib
h*nmol/LAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Unbound AUC0-∞: Area Under the Concentration-Time Curve From Time 0 to Infinity for Alisertib304.3 ± 119.09937.6 ± 428.98778.0 ± 610.51
Statistical analysis
  • Alisertib: Normal Hepatic Function vs Alisertib: Moderate Hepatic Impairment vs Alisertib: Severe Hepatic Impairment · Least squares geometric mean ratio: 2.54 · 90% CI 1.84 to 3.53Least Squares Geometric Mean Ratio=Moderate + Severe Hepatic Impairment/Normal Hepatic Function
SecondaryPercentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event

An adverse event is any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent adverse event is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Baseline to 30 days after last dose (Up to 312 Days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event
percentage of participantsAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event100100100
SecondaryPercentage of Participants Who Experienced at Least 1 Serious Adverse Event

A serious adverse event is any untoward medical occurrence or effect that at any dose of a drug results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is medically important due to other reasons than the above mentioned criteria.

Time frame:
Baseline to 30 days after last dose (Up to 312 Days)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced at Least 1 Serious Adverse Event
percentage of participantsAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Percentage of Participants Who Experienced at Least 1 Serious Adverse Event446788
SecondaryPercentage of Participants With Clinically Significant Laboratory Values

Laboratory assessments include serum chemistry and hematology. An abnormal laboratory value was assessed as an AE if that value led to discontinuation or delay in treatment, dose modification, therapeutic intervention, or was considered by the investigator to be a clinically significant change from baseline.

Time frame:
Baseline to the end of the study (Up to 312 Days)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Laboratory Values
percentage of participantsAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Gamma-glutamyltransferase increased1300
Alanine aminotransferase increased080
Aspartate aminotransferase increased080
Blood bilirubin increased080
Transaminases increased080
Blood sodium decreased680
Blood calcium increased600
Blood phosphorus decreased600
Platelet count decreased680
Blood alkaline phosphatase increased680
Blood creatinine increased080
Neutrophil count decreased080
White blood cell count decreased080
SecondaryPercentage of Participants With Clinically Significant Vital Signs

Vital signs include measurements of sitting diastolic and systolic blood pressure, heart rate, and temperature. Any vital signs determined by the investigator to be clinically significant were recorded as AEs.

Time frame:
Baseline to the end of the study (Up to 312 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Clinically Significant Vital Signs
percentage of participantsAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Pyrexia25838
Sinus tachycardia600
SecondaryCmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2
Time frame:
Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Reported as:
Mean · nmol/L
Cmax: Maximum Observed Plasma Concentration for Alisertib Metabolites M1 and M2
nmol/LAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Metabolite M1370.3 ± 282.021774.0 ± 904.102001.9 ± 1094.75
Metabolite M2154.6 ± 82.54173.8 ± 54.39207.3 ± 151.60
SecondaryTmax: Time of First Occurrence of Cmax for Alisertib Metabolites M1 and M2
Time frame:
Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Reported as:
Median · hours
Tmax: Time of First Occurrence of Cmax for Alisertib Metabolites M1 and M2
hoursAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Metabolite M13.500 (1.88 to 7.92)24.000 (1.00 to 48.30)24.150 (9.08 to 96.70)
Metabolite M29.000 (5.88 to 49.30)24.050 (9.00 to 72.10)24.150 (9.08 to 96.70)
SecondaryAUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2

The area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (AUC0-last) of the alisertib metabolites M1 and M2 was determined from the concentration-time curve of each participant using non-compartmental methods.

Time frame:
Cycle 1 Day 1 Pre-dose and, and at multiple timepoints (up to 168 hours) post-dose
Reported as:
Mean · h*nmol/L
AUClast: Area Under the Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Alisertib Metabolites M1 and M2
h*nmol/LAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Metabolite M18366.3 ± 10790.88159665.0 ± 116960.23196750.0 ± 117472.08
Metabolite M28923.1 ± 6539.0017326.0 ± 8562.9616987.5 ± 9384.25
SecondaryDose-normalized Trough Concentration of Alisertib on Cycle 1 Day 14

A single blood sample will be collected pre-dose on Cycle 1 Day 14. The concentration of alisertib was determined in the plasma sample and dose-normalized.

Time frame:
Pre-dose on Day 14 of Cycle 1

No measurements were reported for this outcome.

Adverse events

Collected over First dose of study drug to 30 days past last dose (Up to 312 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alisertib: Normal Hepatic Function2/16 (12.5%)7/16 (43.8%)15/16 (93.8%)
Alisertib: Moderate Hepatic Impairment3/12 (25%)8/12 (66.7%)12/12 (100%)
Alisertib: Severe Hepatic Impairment4/8 (50%)7/8 (87.5%)8/8 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
Abdominal painGastrointestinal disorders0/162/123/8
Colorectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/160/121/8
Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/160/121/8
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/160/121/8
StomatitisGastrointestinal disorders0/160/121/8
PyrexiaGeneral disorders2/160/121/8
HyperbilirubinaemiaHepatobiliary disorders0/160/121/8
Hepatic failureHepatobiliary disorders0/160/121/8
Biliary tract infectionInfections and infestations0/160/121/8
SepsisInfections and infestations0/160/121/8
Most frequent other events
Showing 10 of 135
Most frequent other events
EventAlisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic Impairment
NauseaGastrointestinal disorders9/163/120/8
AscitesGastrointestinal disorders0/166/121/8
ThrombocytopeniaBlood and lymphatic system disorders1/165/120/8
HyperbilirubinaemiaHepatobiliary disorders0/165/120/8
DiarrhoeaGastrointestinal disorders6/164/120/8
FatigueGeneral disorders6/163/123/8
AlopeciaSkin and subcutaneous tissue disorders6/163/121/8
VomitingGastrointestinal disorders4/164/120/8
DehydrationMetabolism and nutrition disorders1/164/120/8
ConstipationGastrointestinal disorders5/162/120/8

Baseline characteristics

Safety population was defined as all participants who received at least 1 dose of alisertib.

Age, Continuous
Age, Continuous(years)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
Mean61.2 ± 10.0754.9 ± 9.8954.0 ± 7.0557.5 ± 9.77
Sex: Female, Male
Sex: Female, Male(Participants)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
Female57214
Male115622
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
Hispanic or Latino1124
Not Hispanic or Latino1411631
Not Reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
White1411631
Black or African American2125
Region of Enrollment
Region of Enrollment(Participants)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
United States1612836
Height
Height(cm)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
Mean172.9 ± 14.62162.9 ± 7.79178.2 ± 8.10170.1 ± 12.66
Weight
Weight(kg)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
Mean84.6 ± 20.99785.5 ± 33.88185.8 ± 11.84785.2 ± 24.044
Body surface area
Body surface area(m^2)Alisertib: Normal Hepatic FunctionAlisertib: Moderate Hepatic ImpairmentAlisertib: Severe Hepatic ImpairmentTotal
Mean2.030 ± 0.30731.897 ± 0.40282.056 ± 0.19701.986 ± 0.3292
08

Study locations

7 sites
  • Miami, Florida, United States
  • Chicago, Illinois, United States
  • Ann Arbor, Michigan, United States
  • Saint Louis, Missouri, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2014 to primary completion in Apr 2016, 19 months.

Results were first posted in Nov 2018, 2 years 7 months after primary completion.

Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 19 months is below that.

Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2014
First posted
Aug 12, 2014
StartActual
Aug 21, 2014
Primary completionActual
Apr 5, 2016
CompletionActual
Jul 18, 2016
Results first posted
Nov 15, 2018
Last update
Nov 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02214147
Responsible party
Sponsor
First posted
Aug 12, 2014
Start date
Aug 21, 2014
Primary completion
Apr 5, 2016
Completion
Jul 18, 2016
Results posted
Nov 15, 2018
Last update
Nov 15, 2018

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MLN 8237

Start the discussion